Everything below concerns preclinical model. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-09. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
== Scientists and inventors == Samuel Bard* (1763), personal physician to George Washington; founder of the Columbia University College of Physicians and Surgeons John Stevens (King's 1768), builder of the first oceangoing steamboat in the U.S. Nicholas Romayne* (1774), physician, president of the Columbia University College of Physicians and Surgeons David Hosack (1790), physician, botanist, educator John Eatton Le Conte (1800), naturalist Samuel Akerly (1804), physician, co-founder of the New York Institute for the Education of the Blind Valentine Mott (1806), surgeon pioneer James Renwick (1807), English-American scientist and engineer, professor of Natural philosophy at Columbia University; father of architect James Renwick Jr. John Brodhead Beck (1813), New York physician Daniel Levy Maduro Peixotto (1816), Dutch-born Jewish American physician, former president of the Willoughby Medical College Henry James Anderson (1818), scientist and educator who participated in the U.S. Dead Sea exploration expedition Alfred Charles Post (1822), surgeon, professor at New York University School of MedicineS Horatio Allen (1823), imported the Stourbridge Lion, first successful steam locomotive to run in the U.S. John Clarkson Jay (1827), physician and notable conchologist, grandson of John Jay Alfred W. Craven (1829), chief engineering of Croton Aqueduct; founding member of the American Society of Civil Engineers Edward S.
=== Acute wounds === An acute wound is any wound which results from direct trauma and progresses through the four stages of wound healing along an expected timeline. The first stage, hemostasis, lasts from minutes to hours after initial injury. This stage is followed by the inflammatory phase which typically lasts 1 to 3 days. Proliferation is the third stage of wound healing and lasts from a few days up to a month. The fourth and final phase of wound healing, remodeling/scar formation, typically lasts 12 months but can continue as long as 2 years after the initial injury. Acute wounds can further be classified as either open or closed. An open wound is any injury whereby the integrity of the skin has been disrupted and the underlying tissue is exposed. A closed wound, on the other hand, is any injury in which underlying tissue has been damaged but the overlying skin is still intact.
4-HO-DPT acts as a high-efficacy partial agonist to full agonist of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors. It has more than two orders of magnitude greater potency as an agonist of the serotonin 5-HT2A and 5-HT2B receptors than as an agonist of the serotonin 5-HT2C receptor. Hence, it shows considerable selectivity for the serotonin 5-HT2A receptor over the serotonin 5-HT2C receptor. Compared to psilocin (4-HO-DMT), 4-HO-DPT has about the same potency and efficacy as a serotonin 5-HT2A receptor agonist, has about the same potency but is much more efficacious as a serotonin 5-HT2B receptor agonist (EmaxTooltip maximal efficacy = 39% vs. 94%, respectively), and has about the same efficacy but approximately 10-fold lower potency as a serotonin 5-HT2C receptor agonist. 4-HO-DPT produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. Its potency for inducing the head-twitch response in mice is about 4- or 5-fold lower than that of psilocin.
Sources: en.wikipedia.org
== History == The first example of a palladium catalyzed coupling of aryl halides with organotin reagents was reported by Colin Eaborn in 1976. This reaction yielded from 7% to 53% of diaryl product. This process was expanded to the coupling of acyl chlorides with alkyl-tin reagents in 1977 by Toshihiko Migita, yielding 53% to 87% ketone product.
In order for a protonated acid to lose a proton, the pH of the system must rise above the pKa of the acid. The decreased concentration of H+ in that basic solution shifts the equilibrium towards the conjugate base form (the deprotonated form of the acid). In lower-pH (more acidic) solutions, there is a high enough H+ concentration in the solution to cause the acid to remain in its protonated form. Solutions of weak acids and salts of their conjugate bases form buffer solutions. To determine the concentration of an acid in an aqueous solution, an acid–base titration is commonly performed. A strong base solution with a known concentration, usually NaOH or KOH, is added to neutralize the acid solution according to the color change of the indicator with the amount of base added. The titration curve of an acid titrated by a base has two axes, with the base volume on the x-axis and the solution's pH value on the y-axis. The pH of the solution always goes up as the base is added to the solution.
Agents that "bind" to the toxin can reduce free or active toxin present. It is possible for this binding to be nonspecific or specific. Activated charcoal is the non-specific binding agent most frequently utilised as it has strong adsorption capacity and could prevent the toxin's enterohepatic recirculation. Chelation agents, immunotherapy, and bioscavenger therapy are examples of specific binders. Urinary alkalization or hemadsorption may improve elimination in some circumstances.
Because even the longest-lived isotope of technetium has a relatively short half-life (4.21 million years), the 1952 detection of technetium in red giants helped to prove that stars can produce heavier elements.
Sources: en.wikipedia.org
Russia's goals in the war are described as manyfold: Restoring the security of its peacekeepers and 'citizens' in South Ossetia, the establishment of Abkhazia and South Ossetia as military protectorates, a weakening of Georgia's strategic position (as a means to dissuade NATO from offering a MAP to Georgia and to diminish the attractiveness of the energy transit corridor from the Caspian) and toppling the government of President Saakashvili. In 2008, Professor of Political Science Robert O. Freedman argued that it was support of the anti-American rogue states and terrorists that "set the stage for the invasion of Georgia as Putin sought to spread Russian influence throughout the South Caucasus as well as the Middle East." Putin gave Russian passports to people living in the separatist regions so Russia could use Georgian military response to South Ossetian attacks as a pretext for Russian military invasion for protection of Russian citizens.
Accurate recording of the volume of drainage as well as the contents is vital to ensure proper healing and monitor for excessive bleeding. The amount of drained fluids can be used to determine when the drain should be removed. Drains will have protective dressings that will need to be changed daily/as needed.
The SI unit of pressure is the pascal (symbol Pa), but vacuum is often measured in torrs, named for an Italian physicist Torricelli (1608–1647). A torr is equal to the displacement of a millimeter of mercury (mmHg) in a manometer with 1 torr equaling 133.3223684 pascals above absolute zero pressure. Vacuum is often also measured on the barometric scale or as a percentage of atmospheric pressure in bars or atmospheres. Low vacuum is often measured in millimeters of mercury (mmHg) or pascals (Pa) below standard atmospheric pressure. "Below atmospheric" means that the absolute pressure is equal to the current atmospheric pressure. In other words, most low vacuum gauges that read, for example 50.79 Torr. Many inexpensive low vacuum gauges have a margin of error and may report a vacuum of 0 Torr but in practice this generally requires a two-stage rotary vane or other medium type of vacuum pump to go much beyond (lower than) 1 torr.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.